Clarity Pharmaceuticals Reaches 383-Patient Target in Phase III Prostate Cancer Imaging Trial
Bitget2026/10/27 01:23- Clarity Pharmaceuticals has dosed its target of 383 participants in the Phase III CLARIFY prostate cancer imaging trial.
- The trial evaluates 64Cu-SAR-bisPSMA’s sensitivity and specificity for detecting pelvic lymph node cancer using same-day and next-day imaging, with histopathology as reference.
- Topline CLARIFY results are expected in the first half of 2027, alongside results from AMPLIFY, which studies recurrent prostate cancer.
- Final CLARIFY results are intended to support a US FDA application for the imaging agent’s use before definitive prostate cancer treatment.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitmine Buys 9,587 ETH as Holdings Near 5% of Ethereum Supply
Ekopak Expands Wastewater Treatment Plant at Mark Anthony Brewing
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
Crypto prices
More
